Skip to main content
Search
Search
Advanced Search
Skip main navigation
Open access
Research Article
6 June 2025

Expert perspectives on the use of safinamide for Parkinson’s disease in Portugal: insights from a Portuguese Delphi Consensus

Authors: Ana Margarida Rodrigues [email protected], Cristina Costa, Miguel Gago, Miguel Grunho, Leonor Correia Guedes, Ana Morgadinho, Maria José Rosas, Rita Simões, and Ana Graça VelonAuthor Info & Affiliations
Volume 14, Number 7
https://doi.org/10.57264/cer-2024-0228
PDFFormats

Abstract

Aim: Safinamide is an approved medication for managing motor fluctuations in Parkinson’s disease (PD). However, limited data exist regarding its application in clinical practice in Portugal and the perspectives of Portuguese neurologists on its use. To address this, a group of Portuguese specialists with recognized expertise in PD management convened to compile the insights on various aspects of safinamide use in PD patients among the field and to develop recommendations aimed at informing and guiding physicians in Portugal on its optimal clinical application. Materials & methods: A focus group composed of nine Portuguese PD experts developed a questionnaire building on the 2022 European Delphi study, and employed a Delphi methodology approach to gather the views of Portuguese neurologists with a minimum of 5 years of clinical experience with safinamide (n = 35). A final online questionnaire comprising 35 statements was administered in a single-round Delphi format, utilizing a 5-point Likert scale. Consensus was defined as achieving ≥66% agreement or disagreement among the panelists. Results: A strong consensus emerged among Portuguese neurologists regarding the therapeutic efficacy of safinamide in addressing motor symptoms, motor fluctuations and quality of life. Additionally, agreement was reached on its positive effects on nonmotor symptoms such as sleep, fatigue, mood, quality of life and pain management. However, no consensus was achieved regarding safinamide’s efficacy in managing orthostatic hypotension, cognitive issues, urinary and sexual dysfunction, as well as its safety profile in PD patients with hallucinations. Overall, the opinions of Portuguese neurologists aligned closely with those of their European counterparts. Conclusion: This Delphi study highlights the consensus among Portuguese neurologists on the efficacy of safinamide for managing motor symptoms in PD. The considerations presented herein offer essential guidance for effectively managing PD with safinamide, ultimately enhancing patient care in Portugal.

Plain language summary: Expert views on using safinamide for Parkinson’s disease management in Portugal

What is this article about?

This article discusses how Portuguese neurologists view the use of safinamide in treating Parkinson’s disease (PD). Safinamide is a medication that helps manage movement difficulties and other symptoms in PD patients. The article provides insights from a group of experts in Portugal who discussed the medication’s effectiveness and developed recommendations for its use in clinical practice.

What methodology is described?

A group of nine Portuguese PD specialists developed a questionnaire based on a 2022 European study, which included 35 statements about safinamide’s effects. The experts then provided their opinions on these statements using a 5-point scale. A consensus was reached when at least 66% of the panel agreed on a statement. The results showed that most neurologists agreed on safinamide’s effectiveness in managing motor symptoms and improving quality of life.

What do the results mean? Why is this important?

The findings highlight that safinamide is effective in treating motor symptoms and improving quality of life for PD patients in Portugal. The experts also agreed on its positive effects on nonmotor symptoms like sleep, fatigue and mood. However, there was no consensus on its effectiveness for issues like cognitive problems or sexual dysfunction. These insights are important because they provide doctors in Portugal with clear guidance on how to use safinamide effectively, helping to improve patient care and treatment outcomes.

Supplementary Material

File (supplementary figure.docx)

References

Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
Saini N, Singh N, Kaur N et al. Motor and non-motor symptoms, drugs, and their mode of action in Parkinson's disease (PD): a review. Med. Chem. Res. 33(4), 580–599 (2024).
Google Scholar
2.
Munhoz RP, Tumas V, Pedroso JL, Silveira-Moriyama L. The clinical diagnosis of Parkinson's disease. Arq. Neuropsiquiatr. 82(6), 1–10 (2024).
Google Scholar
3.
Kumaresan M, Khan S. Spectrum of non-motor symptoms in Parkinson's disease. Cureus 13(2), e13275 (2021).
PubMed
Google Scholar
4.
van der Meer F, Jorgensen J, Hiligsmann M. Burden of non-motor symptoms of Parkinson's disease: cost-of-illness and quality-of-life estimates through a scoping review. Expert Rev. Pharmacoecon. Outcomes Res. 25(1), 17–27 (2025).
PubMed
Google Scholar
5.
Ahlskog JE. Parkinson's disease progression is multifaceted: evidence for the underlying benchmarks. Parkinsonism Relat. Disord. 121, 106037 (2024).
PubMed
Google Scholar
6.
Brigas HC, Rodrigues AM, Morgadinho A, Gago MF, Simoes RM. Living with Parkinson's disease in Portugal: Findings from PRISM study. Parkinsonism Relat. Disord. 128, 107124 (2024).
PubMed
Google Scholar
• Uncovers the burden of Parkinson’s disease (PD) among Portuguese patients, revealing current treatment methods, impact on daily life and healthcare resources employed in Portugal.
7.
Obeso JA, Olanow CW, Nutt JG. Levodopa motor complications in Parkinson's disease. Trends Neurosci. 23(Suppl. 10), S2–S7 (2000).
PubMed
Google Scholar
8.
Muller T, Foley P. Clinical pharmacokinetics and pharmacodynamics of safinamide. Clin. Pharmacokinet. 56(3), 251–261 (2017).
PubMed
Google Scholar
9.
Bovenzi R, Liguori C, Canesi M et al. Real-world use of Safinamide in motor fluctuating Parkinson's disease patients in Italy. Neurol. Sci. 45(2), 573–583 (2024).
PubMed
Google Scholar
10.
Nishikawa N, Hatano T, Nishioka K et al. Safinamide as adjunctive therapy to levodopa monotherapy for patients with Parkinson's disease with wearing-off: The Japanese observational J-SILVER study. J. Neurol. Sci. 461, 123051 (2024).
PubMed
Google Scholar
11.
European Medicines Agency. Xadago (safinamide) [summary of product characteristics]. (2015). Accessed: 18 October 2024: https://www.ema.europa.eu/en/documents/product-information/xadago-epar-product-information_en.pdf
Google Scholar
12.
Kulisevsky J, Ferraz HB, Suppa A, Reichmann H. Effects of safinamide on motor and non-motor symptoms in patients with Parkinson's disease and motor fluctuations. Eur. Neurol. 87(5–6), 291–305 (2024).
PubMed
Google Scholar
•• This meta-analysis evaluates the efficacy of safinamide as an add-on therapy to levodopa for PD patients with motor fluctuations.
13.
Wei Q, Tan Y, Xu P et al. The XINDI Study: a randomized phase III clinical trial evaluating the efficacy and safety of safinamide as add-on therapy to levodopa in Chinese patients with Parkinson's disease with motor fluctuations. CNS Drugs 36(11), 1217–1227 (2022).
PubMed
Google Scholar
14.
Hattori N, Tsuboi Y, Yamamoto A et al. Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: a randomized, double-blind, placebo-controlled, phase II/III study. Parkinsonism Relat. Disord. 75, 17–23 (2020).
PubMed
Google Scholar
15.
Kurihara K, Mishima T, Fujioka S, Tsuboi Y. Efficacy and safety evaluation of safinamide as an add-on treatment to levodopa for Parkinson's disease. Expert Opin. Drug Saf. 21(2), 137–147 (2022).
PubMed
Google Scholar
16.
Abbruzzese G, Kulisevsky J, Bergmans B et al. A European observational study to evaluate the safety and the effectiveness of safinamide in routine clinical practice: The SYNAPSES Trial. J. Parkinsons Dis. 11(1), 187–198 (2021).
PubMed
Google Scholar
17.
Stocchi F, Antonini A, Berg D et al. Safinamide in the treatment pathway of Parkinson's disease: a European Delphi Consensus. NPJ Parkinsons Dis. 8(1), 17 (2022).
PubMed
Google Scholar
•• Overview of how European movement disorders specialists view the role of safinamide in their clinical practice, through a Delphi panel methodology.
18.
Valldeoriola F, Grandas F, Arbelo JM et al. Spanish expert consensus on the use of safinamide in Parkinson's disease. Neurologia (Engl. Ed.) 36(9), 666–672 (2018).
Google Scholar
•• This consensus provides clinical management guidelines for safinamide based on the opinion of a group of Spanish experts in movement disorders.
19.
Nasa P, Jain R, Juneja D. Delphi methodology in healthcare research: how to decide its appropriateness. World J. Methodol. 11(4), 116–129 (2021).
PubMed
Google Scholar
20.
Taylor E. We Agree, Don't We? The Delphi method for health environments research. HERD 13(1), 11–23 (2020).
PubMed
Google Scholar
21.
Teixeira FG, Gago MF, Marques P et al. Safinamide: a new hope for Parkinson's disease? Drug Discov. Today 23(3), 736–744 (2018).
PubMed
Google Scholar
22.
Bette S, Shpiner DS, Singer C, Moore H. Safinamide in the management of patients with Parkinson's disease not stabilized on levodopa: a review of the current clinical evidence. Ther. Clin. Risk Manag. 14, 1737–1745 (2018).
PubMed
Google Scholar
23.
Cattaneo C, Kulisevsky J. The effects of safinamide in Chinese and non-Chinese patients with Parkinson's disease. Adv. Ther. 41(2), 638–648 (2024).
PubMed
Google Scholar
24.
Wasan H, Singh D, Kh R. Safinamide in neurological disorders and beyond: evidence from preclinical and clinical studies. Brain Res. Bull. 168, 165–177 (2021).
PubMed
Google Scholar
25.
Jenner P, Caccia C. The role of glutamate in the healthy brain and in the pathophysiology of Parkinson's Disease. Eur. Neurol. Rev. 14, 2–12 (2019).
Google Scholar
26.
Wang J, Wang F, Mai D, Qu S. Molecular mechanisms of glutamate toxicity in Parkinson's disease. Front. Neurosci. 14, 585584 (2020).
PubMed
Google Scholar
27.
Antonini A, Martinez-Martin P, Chaudhuri RK et al. Wearing-off scales in Parkinson's disease: critique and recommendations. Mov. Disord. 26(12), 2169–2175 (2011).
PubMed
Google Scholar
28.
Stocchi F, Antonini A, Barone P et al. Early detection of wearing off in Parkinson disease: the DEEP study. Parkinsonism Relat. Disord. 20(2), 204–211 (2014).
PubMed
Google Scholar
29.
Nomoto M, Ishida T, Koebis M et al. Characteristics of wearing-off and motor symptoms improved by safinamide adjunct therapy in patients with Parkinson's disease: a post hoc analysis of a Japanese phase II/III study. J. Neurol. Sci. 434, 120083 (2022).
PubMed
Google Scholar
30.
Cattaneo C, Jost WH, Bonizzoni E. Long-term efficacy of safinamide on symptoms severity and quality of life in fluctuating Parkinson's disease patients. J. Parkinsons Dis. 10(1), 89–97 (2020).
PubMed
Google Scholar
•• Investigates the effects of safinamide over 2-year treatment on PD symptoms severity and quality of life.
31.
European Medicines Agency. Xadago (safinamide) [summary of product characteristics]. (2015). Accessed: 22 October 2024: https://www.ema.europa.eu/en/documents/product-information/xadago-epar-product-information_en.pdf
Google Scholar
32.
Stocchi F, Vacca L, Grassini P et al. Overnight switch from rasagiline to safinamide in Parkinson's disease patients with motor fluctuations: a tolerability and safety study. Eur. J. Neurol. 28(1), 349–354 (2021).
PubMed
Google Scholar
33.
Rinaldi D, Bianchini E, Sforza M et al. The tolerability, safety and efficacy of safinamide in elderly Parkinson's disease patients: a retrospective study. Aging Clin. Exp. Res. 33(6), 1689–1692 (2021).
PubMed
Google Scholar
34.
Tan YY, Jenner P, Chen SD. Monoamine oxidase-B inhibitors for the treatment of Parkinson's disease: past, present, and future. J. Parkinsons Dis. 12(2), 477–493 (2022).
PubMed
Google Scholar
35.
Borgohain R, Szasz J, Stanzione P et al. Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations. Mov. Disord. 29(2), 229–237 (2014).
PubMed
Google Scholar
36.
Borgohain R, Szasz J, Stanzione P et al. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease. Mov. Disord. 29(10), 1273–1280 (2014).
PubMed
Google Scholar
37.
Rinaldi D, Sforza M, Assogna F et al. Safinamide improves executive functions in fluctuating Parkinson's disease patients: an exploratory study. J. Neural Transm. (Vienna). 128(2), 273–277 (2021).
PubMed
Google Scholar
38.
Rodriguez-Jorge F, Beltran-Corbellini A, Chico-Garcia JL et al. Efficacy and safety of high doses of safinamide in advanced Parkinson disease. Parkinsonism Relat. Disord. 97, 73–74 (2022).
PubMed
Google Scholar
39.
Aldian FM, Ariyanto MV, Atmaja MSS. Efficacy and safety of safinamide vs opicapone as adjuvant to levodopa therapy in elderly with Parkinson's disease: a network meta-analysis. J. Asian Med. Students Assoc. doi: (2023).
Google Scholar
40.
Cilia R, Cereda E, Piatti M et al. Levodopa equivalent dose of safinamide: a multicenter, longitudinal, case-control study. Mov. Disord. Clin. Pract. 10(4), 625–635 (2023).
PubMed
Google Scholar
41.
Bovenzi R, Conti M, Pierantozzi M et al. Safinamide effect on sleep architecture of motor fluctuating Parkinson's disease patients: a polysomnographic rasagiline-controlled study. Parkinsonism Relat. Disord. 127, 107103 (2024).
PubMed
Google Scholar
42.
Simoes R, Goncalves A, Ferreira J. Is safinamide helpful in multiple system atrophy? In: Movement Disorders. Wiley, NJ, USA (2019).
Google Scholar
43.
Rizzone MG, Mancini F, Artusi CA et al. Efficacy of safinamide as add-on therapy after subthalamic nucleus deep brain stimulation in Parkinson disease. Neurol. Sci. 43(5), 3187–3193 (2022).
PubMed
Google Scholar
44.
INFARMED – Autoridade Nacional do Medicamento e Produtos de Saúde IP. Relatório de avaliação do pedido de comparticipação de medicamento para uso humano: safinamida. (2016).
Google Scholar
|